EnCompass Technologies

Executive Summary

EnCompass Technologies is a San Diego-based medical device company developing F2, an advanced embolic protection system designed to prevent brain injury and stroke during cardiac procedures such as Transcatheter Aortic Valve Replacement (TAVR). Traditional TAVR carries a risk of particulate debris dislodging and traveling to the brain, affecting nearly one million patients globally each year. EnCompass's F2 filtration technology aims to capture these emboli, offering a more effective solution than existing devices. The company was founded in 2018 and operates in the Drug Delivery and Digital Health sectors, though its core focus is mechanical filtration. While still in a private, pre-revenue stage (no funding or valuation disclosed), EnCompass addresses a clear, high-volume clinical need with significant potential for adoption if clinical evidence demonstrates superiority. The expected market is large and growing with the expansion of TAVR procedures.

Upcoming Catalysts (preview)

• Q3 2026Initial clinical trial results for F2 embolic protection system60% success
• Q1 2027FDA 510(k) submission or breakthrough device designation50% success
• Q2 2027Strategic partnership or distribution agreement with a major cardiovascular company40% success